Marc LeBel is currently the President of Nuchem Sciences, a drug discovery and chemical development contract research organization based in Montréal, Québec, Canada. Marc brings his vast experience as co-founder of Anapharm, a Phase I CRO which grew from 8 employees to 1200 employees with revenues of more than 150M$. As President and then CEO of Anapharm, Marc expanded the company from Quebec City to Trois-Rivières, Montréal, Toronto and Barcelona.

He also served as executive Vice-President of PharmaNet, from 2005 to 2007, following the acquisition of Anapharm. He was also interim CEO of Warnex Inc., 2012-2013 where he led the process that led to the sale of Warnex Bioanalytical to Biotrials.

He was also an active member of the following boards of Directors: Université Laval, Acasti Inc, Asmacure and Nuchem Therapeutics. He is the author of 120 publications and more than 130 communications.

Marc received the Excelsia 2006 from BioQuébec, the leadership prize from the Canadian Society of Pharmaceutical Sciences and the Prix des Grands Diplômés from Université Laval.